Adaptive Biotechnologies
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 98.4m | 154m | 185m | 170m | 173m | 207m | 265m |
| % growth | 16 % | 57 % | 20 % | (8 %) | 1 % | 20 % | 28 % |
| EBITDA | (151m) | (207m) | (194m) | (164m) | (91.1m) | (53.2m) | (19.3m) |
| % EBITDA margin | (154 %) | (134 %) | (105 %) | (96 %) | (53 %) | (26 %) | (7 %) |
| Profit | (146m) | (207m) | (200m) | (225m) | (182m) | (152m) | (115m) |
| % profit margin | (149 %) | (134 %) | (108 %) | (132 %) | (105 %) | (73 %) | (43 %) |
| EV / revenue | 75.2x | 23.4x | 3.2x | 3.8x | 3.9x | 3.3x | 2.9x |
| EV / EBITDA | -49.0x | -17.4x | -3.1x | -4.0x | -7.3x | -12.7x | -39.2x |
| R&D budget | 116m | 142m | 142m | 122m | - | - | - |
| R&D % of revenue | 118 % | 92 % | 76 % | 72 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $4.6m | Series A | |
| N/A | $5.8m | Series B | |
| N/A | $2.5m | Grant | |
$100m | Series D | ||
$5.0m | Series C | ||
| N/A | $94.0m | Series E | |
$195m Valuation: $1.1b | Series F | ||
N/A | Secondary | ||
| N/A | N/A | IPO | |
| N/A | N/A | Post IPO Equity | |
| N/A | N/A | Post IPO Equity | |
* | $125m | Post IPO Debt | |
| Total Funding | AUD629m | ||
Related Content
Recent News about Adaptive Biotechnologies
EditAdaptive Biotechnologies is a pioneering company in the biotechnology sector, focusing on leveraging the power of the immune system to transform the diagnosis and treatment of diseases. The company operates primarily in the healthcare and life sciences markets, serving a diverse range of clients including medical researchers, healthcare providers, and pharmaceutical companies.
Adaptive Biotechnologies specializes in decoding the genetic information of immune cell receptors. These receptors are crucial because they help the immune system recognize and respond to diseases. By understanding these receptors, the company aims to develop better diagnostic tools and treatments. One of their notable initiatives is the ImmuneRACE study, which seeks to understand the immune response to COVID-19. Participants in this study provide blood samples and nasal or throat swabs, which are then analyzed to identify immune cell receptors that recognize the virus. This research could lead to improved diagnostics, treatments, and vaccines for COVID-19.
The company's business model revolves around the application of advanced data algorithms to analyze genetic information from immune cells. They generate revenue through partnerships with pharmaceutical companies, licensing their technology, and providing diagnostic services. By offering these specialized services, Adaptive Biotechnologies helps its clients develop more effective therapies and diagnostic tests.
In summary, Adaptive Biotechnologies is at the forefront of using immune system data to drive advancements in healthcare. Their innovative approach not only aids in the fight against COVID-19 but also holds promise for tackling a wide range of other diseases.
Keywords: Biotechnology, Immune System, Diagnostics, COVID-19, Genetic Analysis, Healthcare, Life Sciences, Data Algorithms, Pharmaceutical Partnerships, ImmuneRACE Study.
